Abstract
Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.
| Original language | English |
|---|---|
| Pages (from-to) | 289-294 |
| Number of pages | 6 |
| Journal | Cardiovascular Revascularization Medicine |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access : The DELIVER study. / Polad, Jawed; Wöhrle, Jochen; Singh, Balbir; Chag, Milan; Rha, Seung-Woon; Malik, Fazila Tun Nesa; van Eck, Martijn; Rottbauer, Wolfgang.
In: Cardiovascular Revascularization Medicine, Vol. 15, No. 5, 01.01.2014, p. 289-294.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access
T2 - The DELIVER study
AU - Polad, Jawed
AU - Wöhrle, Jochen
AU - Singh, Balbir
AU - Chag, Milan
AU - Rha, Seung-Woon
AU - Malik, Fazila Tun Nesa
AU - van Eck, Martijn
AU - Rottbauer, Wolfgang
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.
AB - Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.
KW - Deliverability
KW - Radial access
KW - Resolute integrity
KW - Zotarolimus-eluting stent
UR - http://www.scopus.com/inward/record.url?scp=84907308460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907308460&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2014.07.002
DO - 10.1016/j.carrev.2014.07.002
M3 - Article
VL - 15
SP - 289
EP - 294
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
SN - 1553-8389
IS - 5
ER -